Giant etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster
Giant etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster

19 Ağustos 2015 Çarşamba

Cancer Council unaware tobacco giant behind FOI request on child smoking habits

Cancer Council Victoria says it had no concept a British American Tobacco worker was behind a freedom of details request for information on the tobacco use and acquiring habits of 1000′s of school children.


For the past 30 years, the council has surveyed youngsters aged among 12 and 17 about their age, gender and location, accessibility to income, alcohol and tobacco consumption and getting habits, and preferred brands.


The director of the Victorian Cancer Council, Todd Harper, stated a attorney had requested the survey information underneath the Freedom of Information Act, but the request was rejected since it was not in the public interest to release it.


Relevant: Australian teens major charge in eschewing consuming and smoking


It was not right up until Fairfax Media reported the lawyer had appealed towards the determination to Victoria’s Civil and Administrative Tribunal, that the council became mindful the attorney was an employee of the tobacco giant, Harper said.


“We had no idea that British American Tobacco was behind the request,” he said. “All we knew was it was an person from a law firm who wanted the information. I’m disappointed that the tobacco firm wasn’t upfront about its involvement.”


Harper stated the council was concerned that, as soon as manufactured public, the data could be utilized by tobacco and alcohol firms to acquire insight into the purchasing and drug consumption routines of younger folks, as nicely as the varieties of brand names that appealed to them.


The information is utilized by the Cancer Council to assist it recognize exactly where and how to direct publishing health messaging, as effectively as for scientific scientific studies. When mothers and fathers consented to their young children finishing the survey, the did so believing the information would be used only in the curiosity of public health, Harper explained.


Fairfax Media also exposed that the identical attorney utilised the Freedom of Information Act to get info from surveys of adult smokers in that state, which integrated queries about their attitudes toward smoking.


“The Cancer Institute NSW was compelled to give tobacco survey information requested underneath the NSW Government Info [Public access] Act,” its chief cancer officer, David Currow, told Fairfax.


A spokeswoman for British American Tobacco advised Guardian Australia the Victorian data request “wasn’t about children”.


“This is about plain packaging,” she stated. “We did not look for any individual data or info in respect of youngsters. We’ve asked for figures by way of a standard freedom of info request because we want to discover out if plain packaging, a measure introduced with out evidence and that straight influences our business, is possessing the effect the Australian government claims it is.”


In a globe very first, Australia passed plain packaging legislation in 2011, requiring all cigarette packaging to be stripped of marketing and branding, apart from the organization name and health warnings. All tobacco now comes in olive green cardboard containers with graphic overall health messages.


In a series of papers published by the Cancer Council in the BMJ journal Tobacco Control in March, plain packaging was related with an enhance in the variety of men and women pondering about quitting and trying to quit. The investigation also identified kids aged in between twelve and 17 found standardised packaging much less attractive.


An appeal date for the freedom of details request is nevertheless to be set.



Cancer Council unaware tobacco giant behind FOI request on child smoking habits

24 Haziran 2014 Salı

Private hospital giant Spire to unveil £1bn float


The organization, which has 8,000 workers, will be the very first hospital chain to go public. Spire was designed in 2007 when Cinven, the private equity house, purchased a chain of private hospitals that had been carved out of Bupa, the private health insurance giant, and rebranded them Spire Healthcare. It is anticipated to be valued at about £1bn upon listing.




More are anticipated after the summertime, in spite of concerns about a loss of investor appetite for new share issues, which not too long ago prompted Excess fat Face and Blue Inc, the retailers, and Wizz Air, the airline, to shelve float strategies.


Market place self confidence was dented by a series of disappointing debuts like AO Globe, the electrical goods retailer, and Saga, the above-50s vacation group. Nevertheless, considering that then the effective listings of B&ampM Bargains, the low cost retailer, and TSB have aided to restore sentiment.


Spire and SSP, the quick food giant, will be among the last firms to record before the summer, when the City tends to take a break from deal action. The pace of new issues is most likely to reignite in September with British Auto Auctions, the 2nd hand car auctioneer, DFS, the sofa chain, and Aldemore, the new higher street bank, all primed to go.


Earlier this year, Spire was cleared by the Competition watchdog of currently being art of a cabal of big operators that including rivals BMI and HCA that exerted too considerably market dominance. The organization has stated it plans to capture expanding possibilities in the swiftly expanding private healthcare market place where the NHS is expected to spend a greater slice of its spending budget. About 25% of Spire’s patients come from the NHS, up from 18% in 2007, but just £5bn of the £110bn-a-12 months NHS finances go to the private sector.


About half of Spire’s perform comprises orthopaedic procedures this kind of as hip and knee replacements, a developing market. Just lately, the hospital operator has moved into acute care by opening standalone cardiovascular and cancer treatment method centres.


The Spire float is becoming overseen by Bank of America Merrill Lynch, Morgan Stanley, JP Morgan and Numis Securities.


Cinven declined to comment.




Private hospital giant Spire to unveil £1bn float

9 Haziran 2014 Pazartesi

Nick Xenophon urges floor cost on cigarettes to outsmart tobacco giant

Independent senator Nick Xenophon is pushing for a minimum floor price tag on cigarettes to counter a tobacco giant’s “cynical” move to promote discounted packets.


British American Tobacco Australia has launched what it claims is the cheapest legal packet of cigarettes on the industry at $ 13 for a 25-pack.


It is blaming federal government policy for the move, saying it is merely looking for to remain competitive as income of reduce-cost cigarettes soar.


Xenophon has accused the tobacco giant of circumventing laws to discourage individuals from smoking.


He programs to introduce a resolution in the upper home subsequent week to look for a minimum floor price for all cigarettes offered in Australia.


“We want to outsmart massive tobacco in terms of what they’ve carried out with this value-discounting and reduction-major campaign,” he told ABC Television on Monday.


Xenophon will seek advice from with public overall health authorities on the most effective disincentive price but wants to see a minimum of $ twenty for a 25-pack.


It was the very best choice to fight a “deeply cynical” campaign aimed at boosting the ranks of younger smokers, he stated.


Xenophon also dismissed “exaggerated” market claims that plain packaging laws and huge excises were driving up black market place income.



Nick Xenophon urges floor cost on cigarettes to outsmart tobacco giant

3 Haziran 2014 Salı

US bakery giant Panera to swear off artificial substances by 2016

Panera says it will get rid of artificial colors, flavors, sweeteners and preservatives from its foods by 2016, a reflection of the developing distaste people are exhibiting for this kind of elements.


The chain of bakery cafes, which has about 1,800 US areas, is producing the pledge as element of a “Foods Policy” it is unveiling Tuesday that outlines its dedication to “clean” and “simple” substances.


The announcement comes at a time when Panera Bread Co is facing slowing sales growth and functioning to jumpstart its organization through a selection of indicates, this kind of as revamping the occasionally complicated way folks order and get foods and switching baking hours to the daytime to develop a homier truly feel in cafes.


The unveiling of Panera’s sweeping “Meals Policy” also underscores how positioning food items as natural has turn out to be a advertising benefit, irrespective of regardless of whether it brings any dietary positive aspects. Element of the attraction for consumers is that they come to feel far better about what they’re consuming, often because they don’t truly feel as guilty about how several calories they are consuming.


Chipotle, for instance, has acquired in reputation in portion by portraying itself as a a lot more wholesome different to classic rapidly-food chains like McDonald’s. Even Subway not too long ago said it would quit making use of azodicarbonamide in its breads. The ingredient was dubbed the “yoga mat” chemical right after a petition by Vani Hari, who runs FoodBabe.com, noted it was utilized to make yoga mats.


Still, declaring food items as getting organic or free of charge of artificial substances has the potential to invite criticism and even legal troubles. A lawsuit filed in November, for instance, alleges that Entire Meals Marketplace employs a “spectacular array” of artificial substances in some of its shop-brand goods, despite the grocer’s promise that the items have “nothing at all artificial.”


Panera also is not swearing off genetically modified components, yet another problem that is gaining consideration in certain circles. As opposed to Chipotle, which says its menu will quickly be free of charge of GMOs, Panera makes use of as well numerous various elements to be ready to make that declare. And neither chain has any ideas to end promoting fountain sodas from Coca-Cola and PepsiCo, even even though the drinks are sweetened with substantial fructose corn syrup.


As for the rest of its menu, Panera says it is about halfway by means of the removal of artificial elements. It’s nevertheless looking for techniques to removes the artificial colors used in its bakery icings, for instance, and is testing a smoked ham in select markets that isn’t going to use artificial preservatives.


“We made a decision it was time to put all this into a clear and concise policy,” Ron Shaich, Panera’s founder and CEO, explained in an interview.


Ten years in the past, for instance, Panera announced that it would use chicken raised without having antibiotics, a move Shaich said assisted drastically drive product sales.


Panera’s new policy also states the chain’s commitment to “transparency,” that means it will make it straightforward for individuals to see the components and nutritional content material of its meals. It also says it will work to have a “good affect” on the meals method, this kind of as by supporting North American suppliers every time feasible.


Regardless of whether the new policy assists entice much more clients is yet to be seen.


Last yr, Panera’s sales rose 2.six% at firm-owned locations open at least a yr. That was down from 6.5% in 2012 and four.9 % in 2011.


This yr, the St Louis-primarily based firm is forecasting product sales development of two to 3.five%.



US bakery giant Panera to swear off artificial substances by 2016

13 Nisan 2014 Pazar

Drug giant faces bribery claims


GlaxoSmithKline, Britain’s biggest drug business, has been accused of bribing doctors to prescribe their medicines in Europe.




Medical doctors in Poland have been allegedly paid to advertise its asthma drug, Seretide, under the guise of funding for an education programme, a former income rep has claimed. Medics have been also said to have been paid for lectures in the country which did not consider area.




Prosecutors in Lodz are investigating and have charged eleven doctors and a GSK regional manager in connection with alleged corruption, in accordance to a BBC Panorama programme.




GSK, which has a turnover of more than £26 billion, is currently facing bribery allegations in China and Iraq.The most recent claims had been created by Jarek Wisniewiski, who worked as a income rep for the business for eight many years until finally 2012. In 2010, he worked on a marketing and advertising programme in Poland to promote Seretide. He mentioned that, on paper, income was supplied for educating individuals about the drug but claims it was, in actuality, paying doctors to prescribe a lot more of the medicine.




Another former GSK drug rep, who did not want to be identified, claimed they paid neighborhood doctors for lectures that by no means occurred and this would outcome in a higher number of prescriptions.




Wisniewiski stated he advised GSK he was unhappy with the arrangement, which resulted in him currently being sidelined and then later sacked.


GSK advised the programme that it investigated the matter and discovered “evidence of inappropriate communication in contravention of GSK policy by a single employee”, who was “discplined as a result”. It extra that it was “cooperating completely with the CBA (Central Anti-corruption Company).”


Panorama: Who’s Paying out Your Medical professional? is on tomorrow, at eight.30pm, on BBC One particular.




Drug giant faces bribery claims

20 Ocak 2014 Pazartesi

EU proposals could outlaw giant NHS database

Researchers and major health-related charities say the digital storage of mass data will advance medical science, assisting them understand the causes of ailment, spot side-results to new medication and detect outbreaks of infectious illnesses.


Privacy campaigners claim that men and women could be identified by drugs and insurance firms who could use info to target items and profit from people’s illnesses, though officials say this would not be permitted.


Underneath the scheme, patients’ data will be automatically uploaded into the care.data system unless of course an personal chooses to opt out.


Board papers drawn up by Department of Wellness (DoH) officials warn that proposed EU laws to harmonise rules on information protection would not enable such a program – due to the fact they state that men and women must give explicit consent, realizing the distinct purpose for which information is becoming employed.


The paper drawn up by Peter Knight, DoH deputy director of research, details and intelligence, says ministers are now negotiating with member states in Europe because of their worries.


Pamela Forde, data safety officer for the Royal University of Physicians, explained the changes would not only suggest the axing of the database, but would kill off most main research on illness. She mentioned: “The modifications currently being proposed are truly far-reaching and would indicate a lot of large scale analysis would be impossible.”


The Ministry of Defence is major negotiations on the information protection legislation, and ministers have presently expressed concern that present proposals create also a lot bureaucracy and place also substantial a burden on companies.


A spokesman for the Department of Wellness explained: “We are entirely aware of the adverse influence this would have both on care.information and on United kingdom analysis and we are functioning with the Ministry of Justice to negotiate changes.”



EU proposals could outlaw giant NHS database

29 Aralık 2013 Pazar

Four Motives Merck"s R&D Restructuring May Not Save The Drug Giant (Or The Sector)

Last Friday, Wall Street Journal reporters Peter Loftus and Jonathan Rockoff broke the story that Merck Merck is organizing a dramatic R&ampD restructuring.  The purpose is to look externally for far more programs, rather than to count on Merck’s legendary research labs to provide the bulk of the pipeline.  Four “innovation hubs” will be developed, based near Boston, San Francisco, London, and Shanghai.


As Fierce Biotech’s John Carroll pointed out Saturday, this approach, while probably innovative for Merck, is extremely considerably in line with the course the sector has been taking.


Even inside Merck, this move might be far more evolutionary than revolutionary, given their current – and usually productive – efforts to significantly boost their organization development and licensing (BD&ampL) abilities and status, scoring persistently higher on BCG’s annual partnering survey, for instance, following a deliberate push in that course.


The factors for the industry shift are clear: pharma businesses are struggling to build new items, and inner labs aren’t cutting it.  Unanswered, nonetheless, is regardless of whether the shift from R&ampD to S&ampD (i.e. less research, far more search) will be better, or just various.


The root question is really why pharmas struggle to come up with new merchandise – why is not pharma as innovative as it requirements to be?


The effortless reply would be that large pharma has grow to be too bulky, too bureaucratic, insufficiently nimble – it cannot end stumbling over itself.


Despite the fact that these descriptors are largely accurate, they may also not talk to the underlying supply of the issue: inadequate understanding of the underlying biology.


As sensible as we believe we are, and as significantly as we feel we’ve discovered, we truly really don’t recognize the fundamental basis of most serious illnesses – and even in cases the place there’s a discrete underlying lead to we can recognize, human physiology is so unbelievably difficult that successfully focusing on the problem can be prohibitively tough, at least with our present comprehending.


Really do not take my word for it – here’s what Merck’s new head of R&ampD, Roger Perlmutter, told my Forbes colleague Matt Herper in September:



“…if we’re discovering medication, the dilemma is that we just really don’t know ample. We genuinely understand extremely minor about human physiology. We don’t know how the machine functions, so it’s not a shock that when it is broken, we really don’t know how to repair it. The reality that we ever make a drug that gives favorable effects is a bloody miracle because it’s really challenging to realize what went incorrect.”



The stage is not that we shouldn’t try – without a doubt, it is the obligation of every person in biomedicine to marshal the extremely very best information we have in effort to supply the greatest achievable therapy to sufferers presently sick – but rather that these attempts are typically associated with intrinsically minimal probabilities of good results, provided how a lot we just really don’t realize.


Pharma firms shifting towards externally-sourced plans would be valuable if there are wonderful ideas out there that large businesses are missing, or that are not being adequately acknowledged due to inner politics – the renowned “not invented here” issue that has traditionally plagued Merck, as well as most other big businesses.


It is also feasible that externally-sourced applications will be easier to assess objectively and terminate in a timely fashion this could be a important benefit, given the industry’s struggle with this precise challenge.


At the exact same time, sourcing plans externally is unlikely to be a panacea.


1st – and most importantly — there basically could not be sufficient wonderful concepts out there, ideas that meet Merck’s criteria of top to merchandise “that offer unambiguous promotable advantage.”


Second, you might not know – it may well not even be achievable to recognize – a promising product early on.  Slews of medication that proved very impactful have been not acknowledged as useful early in their development cancer drugs Imbruvica (ibrutinib) and Velcade  (bortezomib) come right away to mind.  Conversely, numerous merchandise that appeared like blockbusters crashed and burned, highlighting the challenge (several, such as me, would say utter futility) of predicting commercial overall performance early in the game.  As I’ve long argued and not too long ago highlighted (in the context of this essential publish by David Grainger of Index Ventures), this would recommend a solution (at least for early goods) informed by a deep sense of humility, a preference for empiricism, and an approach that enables several rapid, low-cost shots – successfully the opposite of the “pick the winners” strategy.


Third, it’s straightforward to idealize what you really do not genuinely know.  This is the flip side of the “not invented here” reflex – the concept that external plans may possibly hold the answers to your hopes and dreams.  When you develop a plan internally, you have a tendency to know it very well, warts and all.  It’s always more difficult to recognize external packages as deeply, and they typically come with liabilities it can be challenging to understand or enjoy, even after responsible diligence.  This is true not only in-licensed applications, but also (especially) for early scientific concepts emerging from academic labs it turns out that a lot of the most promising university data – frequently (specially!) that published in the leading journals – does not appear to be robust or reproducible.  Pressure-testing academic theories remains an crucial, expensive, and profoundly undervalued industry action.


Fourth, a particular dilemma connected with BD&ampL in common is the separation of transaction and development – the people who go out and do the discounts are not typically the folks who will commit their days working on the actual program, leading to a significant agency difficulty.   As I’ve mentioned, I’d desire an approach in which the people doing the seeking are also the ones who will be functioning total-time on the plan they deliver in, and thus have far much more skin in the game.



Four Motives Merck"s R&D Restructuring May Not Save The Drug Giant (Or The Sector)